Mindera Health’s Mind.Px can help predict the most appropriate biologic drug for a psoriasis patient, reducing the trial-and-error approach to medication selection and improving outcomes, according to results from The MATCH study.

The new study, which is published in Dermatology and Therapy, found that the Mind.Px test results altered physician behavior and led to faster, more effective patient outcomes.

Dermal Biomarker Patch

Mind.Px uses a dermal biomarker patch that takes only minutes to extract vast anscriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules. This patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.

The MATCH clinical utility study is a 16-week randomized evaluation of the impact of Mind.Px on response to biologic treatment in patients suffering from psoriasis. Results show that access to Mind.Px test reports significantly alters physician behavior and leads to faster, more effective patient outcomes.

The study enrolled 205 patients with moderate to severe psoriasis and randomized to either an “informed” group, who had access to Mind.Px results, or an “uninformed” group, where physicians treated without access to Mind.Px results. Statistical analysis of concordance between the two groups showed that when given access to Mind.Px results, physician behavior was significantly altered (93.1% vs 65.4% concordance, respectively). Furthermore, analysis of patients whose physicians followed Mind.Px results showed not only did more patients reach Psoriasis Area and Severity Index 75 (PASI75) at 12 weeks, but patients improved faster, with patients reaching this endpoint by Week 4.

Exciting Findings

“The findings of the MATCH study are exciting as they demonstrate the application of a precision medicine tool in clinical practice,” says study author Bruce E. Strober, MD, PhD, Co-founder of Central Connecticut Dermatology and Clinical Professor of Dermatology at Yale University School of Medicine in New Haven, CT, in a news release. “Demonstrating that matching up patient biology and biologic drug class can lead to faster achievement of the clinical endpoint realizes the promise of precision medicine.”

Tobin J. Dickerson, PhD, Chief Scientific Officer and Co-founder of Mindera Health, adds, “This study is a large step forward for precision medicine in dermatology. These findings provide Level 1 evidence and validate Mind.Px as a disruptive clinical decision support tool for psoriasis patients. We are excited to bring this innovation to broader market adoption.”